CC-401( CC401 | JNK-401 )

Catalog No. M14359 CAS No. 395104-30-0

CC-401 (JNK-401) is a potent, selective, ATP-competitive pan-JNK inhibitor with Ki of 25-50 nM.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	873	Get Quote
100MG	Get Quote	Get Quote
200MG	Get Quote	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

CC-401
Note

Research use only, not for human use.
Brief Description

CC-401 (JNK-401) is a potent, selective, ATP-competitive pan-JNK inhibitor with Ki of 25-50 nM.
Description

CC-401 (JNK-401) is a potent, selective, ATP-competitive pan-JNK inhibitor with Ki of 25-50 nM, displays >40-fold selectivity over other related kinases; blocks JNK signaling and renal fibrosis in a rat obstructed kidney model, decrease hepatic necrosis and apoptosis after orthotopic liver transplantation and prevent acute renal failure following ischemia/reperfusion associated with renal transplantation in rats.Blood Cancer Phase 1 Discontinued.
In Vitro

CC-401 has at least 40-fold selectivity for JNK compared with other related kinases, including p38, extracellular signal-regulated kinase (ERK), inhibitor of κB kinase (IKK2), protein kinase C, Lck, zeta-associated protein of 70 kDa (ZAP70). In cell-based assays, 1 to 5 μM CC-401 provides specific JNK inhibition. CC-401, a small molecule that is a specific inhibitor of all three JNK isoforms. CC-401 competitively binds the ATP binding site in JNK, resulting in inhibition of the phosphorylation of the N-terminal activation domain of the transcription factor c-Jun. The specificity of this inhibitor is tested in vitro using osmotic stress of the HK-2 human tubular epithelial cell line. CC-401 inhibits sorbitol-induced phosphorylation of c-Jun in a dosage-dependent manner. However, CC-401 does not prevent sorbitol-induced phosphorylation of JNK, p38, or ERK.
In Vivo

The staining of p-JNK is moderately induced in bevazicumab and Oxaliplatin treatments as compared to control, and in the CC-401-treated samples p-cJun content is significantly lower, consistent with effective JNK inhibition. DNA damage is modestly elevated in combined treatments with CC-401. CC-401 treatment from days 7 to 24 slows the progression of proteinuria, which is significantly reduced compared to the no-treatment and vehicle groups at days 14 and 21. However, there is still an increase in the degree of proteinuria at day 21 in CC-401-treated rats compared to proteinuria at day 5. The vehicle and no-treatment groups developed renal impairment at day 24 as shown by an increase in serum creatinine. This is prevented by CC-401 treatment.
Synonyms

CC401 | JNK-401
Pathway

MAPK/ERK Signaling
Target

JNK
Recptor

JNK
Research Area

Cancer
Indication

Blood cancer

Chemical Information

CAS Number

395104-30-0
Formula Weight

388.5
Molecular Formula

C22H24N6O
Purity

>98% (HPLC)
Solubility

——
SMILES

C1CCN(CC1)CCOC2=CC=CC(=C2)C3=NNC4=C3C=C(C=C4)C5=NC=NN5
Chemical Name

3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Uehara T, et al. Transplantation. 2004 Aug 15;78(3):324-32. 2. Ma FY, et al. J Am Soc Nephrol. 2007 Feb;18(2):472-84. 3. Kanellis J, et al. Nephrol Dial Transplant. 2010 Sep;25(9):2898-908.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks